癌症免疫療法市場規模、佔有率、成長分析（按產品類型、應用、形式、最終用戶、分銷管道和地區）—2025 年至 2032 年行業預測

癌症免疫治療市場規模預計將在 2023 年達到 1364 億美元，從 2024 年的 1486.8 億美元成長到 2032 年的 2962.5 億美元，在預測期內（2025-2032 年）的複合年成長率為 9.0%。

由於醫療支出增加、癌症發病率上升、醫療保險覆蓋率改善以及治療技術進步等因素，全球癌症免疫治療市場預計將經歷顯著成長。免疫療法增強了免疫系統對抗多種癌症（從黑色素瘤到肺癌）的能力，其副作用比傳統治療方法更少，並提供長期保護。根據美國癌症研究所的統計，2020年美國將新增超過180萬例癌症病例，凸顯了尋找有效治療方法的迫切性。然而，由於嚴格的法律規範和高昂的開發成本，市場可能面臨挑戰，這可能會限制新進入者並在預測期內減緩該行業的整體進展。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 監管分析

癌症免疫療法市場規模（按產品類型和複合年成長率） (2025-2032)

• 市場概覽
• 查核點抑制劑
• 單株抗體
• 疫苗
• 細胞療法
• 免疫調節藥物
• 溶瘤病毒

癌症免疫治療市場規模（依應用）及複合年成長率（2025-2032）

• 市場概覽
• 肺癌
• 乳癌
• 黑色素瘤
• 多發性骨髓瘤
• 攝護腺癌
• 卵巢癌
• 子宮頸癌
• 胃癌
• 大腸直腸癌
• 頭頸癌
• 其他

癌症免疫療法市場規模（按類型及複合年成長率）（2025-2032）

• 市場概覽
• 靜脈注射（IV）
• 肌肉注射
• 口服

癌症免疫治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 腫瘤診所
• 居家照護
• 其他

癌症免疫治療市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 直銷
• 零售
• 藥局

癌症免疫治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• AstraZeneca plc（UK）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Gilead Sciences, Inc.（USA）
• Sanofi（France）
• Regeneron Pharmaceuticals Inc.（USA）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（UK）
• Daiichi Sankyo Company, Limited（Japan）
• Incyte Corporation（USA）

結論和建議

Cancer Immunotherapy Market size was valued at USD 136.4 billion in 2023 and is poised to grow from USD 148.68 billion in 2024 to USD 296.25 billion by 2032, growing at a CAGR of 9.0% during the forecast period (2025-2032).

The global cancer immunotherapy market is poised for significant growth, driven by factors such as increasing healthcare expenditures, rising cancer incidence, improved access to medical insurance, and advancements in treatment technologies. Immunotherapy, which enhances the immune system's ability to combat various cancers-ranging from melanoma to lung cancer-offers long-lasting protection with fewer side effects compared to traditional treatments. Statistics from the National Cancer Institute highlighted that over 1.8 million new cancer cases were diagnosed in the U.S. in 2020, emphasizing the urgent need for effective therapies. However, the market may face challenges due to stringent regulatory frameworks and high development costs, potentially restricting new entrants and slowing overall progress in the sector during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, Form, End User, Distribution Channel and region. Based on Product Type, the market is segmented into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators and Oncolytic Virus. Based on Application, the market is segmented into Lung Cancer,Breast Cancer, Melanoma, Multiple Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer and Others. Based on Form, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Oncology Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Direct Tenders, Retail Sales and Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Immunotherapy Market

The global cancer immunotherapy market is experiencing significant growth, largely driven by the increasing incidence of various types of cancer around the world. The rising rates of conditions such as lung, breast, colorectal, melanoma, and hematological cancers underscore the urgent need for innovative and effective treatment options. As cancer continues to be one of the leading causes of morbidity and mortality globally, the demand for advanced therapeutic solutions is critical. This scenario emphasizes the importance of creating novel strategies that can effectively tackle the escalating challenges posed by cancer, thereby enhancing patient outcomes and overall public health.

Restraints in the Cancer Immunotherapy Market

The cancer immunotherapy market faces significant challenges that hinder its growth. Over the past decade, the rising incidence of cancer has spurred extensive research and development in the field of cancer treatments. However, as the processes of manufacturing and testing immunotherapies become more elaborate, the associated costs for patients have skyrocketed, ultimately limiting market expansion. Additionally, the potential side effects related to immunotherapy-such as swelling, skin rashes, heart palpitations, and other adverse reactions-can deter patients from pursuing these treatments. Consequently, these factors contribute to the constraints affecting the overall growth of the cancer immunotherapy market.

Market Trends of the Cancer Immunotherapy Market

The Cancer Immunotherapy market is experiencing a dynamic shift towards diversified immunotherapy solutions, driven by an increasing global cancer patient population and accelerated advancements in medical research. Recent innovations, such as the novel method developed by researchers at the University of Texas and MD Anderson Cancer Center for extracting immunotherapy drugs through peptide linkages within the human body, signify a critical evolution in drug development. This approach not only enhances the efficacy of treatments but also opens new avenues for personalized cancer therapies, making it a promising trend that is likely to attract significant investment and foster competitive growth within the sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Regulatory Analysis

Global Cancer Immunotherapy Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

Global Cancer Immunotherapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

Global Cancer Immunotherapy Market Size by Form & CAGR (2025-2032)

• Market Overview
• Intravenous (IV)
• Intramuscular
• Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Oncology Clinics
• Homecare
• Others

Global Cancer Immunotherapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tenders
• Retail Sales
• Pharmacies

Global Cancer Immunotherapy Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Form, End User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Form, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Form, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Form, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Form, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations